Regulatory Intelligence Update
A professionally curated March 2026 briefing covering Australia, New Zealand, Europe, IMDRF, the USA, and the United Kingdom. This issue highlights evolving expectations in OTC branding, medicine scheduling, post-approval safety reporting, real-world evidence, GMP consultation, and clinical trial oversight.
1. Safety-led access changes are accelerating
Australia and New Zealand both signal stronger consumer-safety scrutiny around vitamins and non-prescription access, especially where cumulative exposure risk or general sale thresholds are under review.
2. Safety reporting frameworks are being modernised
EMA and FDA actions on ICH E2D(R1), alongside FDA's final M14 guidance, point to clearer expectations for postapproval reporting, solicited sources, and RWD-based safety study quality.
3. Trial oversight is becoming more adaptive
EMA's public health emergency draft guidance and MHRA's 2026 UK trial approval pathway both reinforce operational readiness, participant protection, and stronger governance under evolving regulatory conditions.
4. Digital and GMP controls remain a core focus
The PIC/S consultation themes around Annex 6 and Annex 15 highlight continued attention on computerised systems, modern manufacturing practice, and risk-based quality management alignment.
Australia — TGA Updates
Practical developments affecting OTC presentation strategy, supplement scheduling, GI product evidence planning, and GMP consultation readiness.
AustraliaOTC umbrella branding assessment guidance updated
The TGA updated guidance to help sponsors determine when an OTC medicine using umbrella branding needs a higher application level. Sponsors proposing a new umbrella segment must assess whether higher review applies and address relevant presentation considerations in their submission.
Naming and presentation strategy can change the assessment pathway, so sponsors should evaluate umbrella architecture early in development and submission planning.
Vitamin B6 products above 50 mg to move to pharmacist supply
The TGA advised that oral vitamin B6 preparations containing more than 50 mg and up to 200 mg per recommended daily dose will become Pharmacist Only Medicines from 1 June 2027, following concerns about peripheral neuropathy and consumer awareness of cumulative exposure.
This is a safety-driven scheduling change for widely used supplements and may affect product positioning, consumer access, counselling requirements, and portfolio review.
TGA posts adopted guideline on GI locally acting therapeutic equivalence studies
The TGA published its adopted international scientific guideline for demonstrating therapeutic equivalence of locally applied, locally acting gastrointestinal products, noting adoption of CPMP/EWP/239/95 Rev. 1, Corr.1 and its status as an addendum to earlier guidance.
This is directly relevant to evidence generation and submission planning for GI products where local action and equivalence strategies must be justified carefully.
PIC/S Annex 6 and Annex 15 concept papers open for comment
The TGA announced public consultation on PIC/S concept papers for Annex 6 and Annex 15 of the GMP Guide. Proposed changes cover medicinal gases, current industry practices, computerised systems, active substance manufacturers, and alignment with ICH Q9 (R1).
GMP stakeholders should review likely implications for validation, quality risk management, and the role of digital systems in manufacturing and control environments.
New Zealand — Medsafe Updates
Classification, prescriber communications, and consultation activity continue to shape medicine access and safety oversight in New Zealand.
New ZealandPrescriber Update highlights safety and Medicines Amendment Act changes
Medsafe's Prescriber Update Vol. 47 No. 1 includes medicine safety articles, recent safety communications, adverse reaction reporting content, and a prescriber-focused overview of the Medicines Amendment Act 2025, including the verification pathway and wider prescribing of unapproved medicines.
This is both a regulatory and pharmacovigilance update for prescribers, with practical implications for unapproved medicine pathways and awareness of current safety communications.
Agenda published for the 76th Medicines Classification Committee meeting
Medsafe published the agenda for the 76th Medicines Classification Committee meeting to be held on 22 April 2026, covering reclassification submissions, new medicines for classification, and consideration of recent Australian scheduling changes for possible New Zealand implementation.
The agenda signals upcoming classification and harmonisation work and may offer an early indicator of possible downstream access or scheduling changes.
Medsafe consults on increasing general sale vitamin D limit
Medsafe opened consultation on a proposal to increase the amount of vitamin D permitted in a general sale medicine from 25 micrograms to 50 micrograms per daily dose, based on an independent expert opinion informed by current literature.
If adopted, this could widen non-prescription vitamin D availability and alter product strategy for sponsors operating across pharmacy and general sale channels.
Europe, IMDRF and USA
Global developments show clear momentum around emergency trial governance, safety reporting modernisation, device reliance, ultra-rare disease pathways, and stronger RWD study expectations.
EU • IMDRF • USAEMA issues draft guidance for clinical trials during public health emergencies
EMA published draft guidance describing how clinical trials may be initiated, adapted, and overseen during EU-level public health emergencies, with emphasis on participant safety, data integrity, regulatory flexibilities, remote safety collection, and continuity of investigational product management.
Sponsors should consider how crisis-era trial governance, remote oversight, and continuity planning can be embedded into preparedness frameworks before urgent use.
EMA sets EU implementation pathway for ICH E2D(R1) safety reporting
EMA published the EU implementation strategy for ICH E2D(R1), clarifying management of post-authorisation safety data from solicited sources and confirming that MAHs have an additional six-month transition period, with EU requirements continuing to be anchored in GVP Module VI.
Transition planning is needed for case-reporting processes, governance documents, and system logic handling solicited and postapproval safety data.
IMDRF publishes playbook for medical device reliance programs
IMDRF released a final playbook to support regulators developing medical device reliance programs, outlining high-level strategies, implementation considerations, and suggested steps across the product lifecycle while preserving flexibility on scope, partner use, and reliance model selection.
This is useful for device oversight and regulatory convergence planning, especially where jurisdictions are building more efficient reliance pathways.
FDA launches draft framework for individualized ultra-rare disease therapies
FDA announced draft guidance describing a framework for targeted individualized therapies for ultra-rare diseases when randomized controlled trials are not feasible, highlighting evidence expectations, use of natural history data, and possible use of master protocols for related product variations.
The draft may shape development strategy, evidence generation, and regulatory planning in settings where conventional study models are impractical.
FDA finalises E2D(R1) guidance on postapproval case safety reports
FDA announced availability of final ICH E2D(R1) guidance updating postapproval safety data definitions and reporting standards, including clarification for newer data sources such as social media, market research programs, and patient support programs in adverse event reporting.
This has direct significance for pharmacovigilance reporting governance, source categorisation, SOPs, and training across postmarketing safety operations.
FDA finalises M14 guidance for RWD safety studies
FDA announced final ICH M14 guidance on planning, designing, analysing, and reporting non-interventional studies using real-world data for medicine safety assessment, covering research questions, data-source selection, variables, bias, confounding, analyses, reporting, and regulatory submission.
This strengthens expectations for postmarketing RWD study design quality and supports more disciplined evidence planning for safety assessment programs.
United Kingdom — MHRA
UK clinical trial reform and GCP inspection response expectations remain key areas for operational readiness in 2026.
United KingdomMHRA publishes new UK clinical trial approval guidance for 2026 regime
MHRA guidance sets out how to apply for UK clinical trial approval from 28 April 2026, including eligibility, required documents, combined review through IRAS, validation timelines, decision pathways, and public registry requirements under the amended Clinical Trials Regulations.
This is a key operational guide for organisations preparing 2026 trial applications and updating internal submission pathways for the revised regime.
MHRA adds new CAPA guidance to GCP inspection page
MHRA updated its Good Clinical Practice guidance to attach new CAPA guidance for responses to GCP inspection findings. The page explains inspection expectations and states organisations must provide a corrective action and preventative action plan following inspection reports.
The update reinforces inspection response and remediation expectations, particularly around how organisations evidence learning, accountability, and CAPA effectiveness.
Editorial analysis
Convergence with local adaptation
Several updates reflect global harmonisation through ICH, PIC/S, and IMDRF, while still preserving local implementation detail. Organisations operating across regions will need both global consistency and local execution discipline.
More explicit expectations for newer evidence sources
Safety data from solicited programs, social media, patient support programs, and RWD studies are being framed more clearly. This raises the importance of governance, source classification, and auditable decision rules.
Access pathways remain under active review
Vitamin B6 and vitamin D developments show that even familiar products can become regulatory priorities when safety signals, cumulative exposure concerns, or consumer-use trends shift.
Inspection readiness is becoming more operational
Trial approvals, emergency oversight, CAPA response quality, and computerised system controls all point to one direction: regulators want practical evidence that systems can perform reliably under pressure, not only policy statements on paper.
Disclaimer
This article is provided for educational and informational purposes only. It is intended to support general understanding of regulatory concepts and good practice and does not constitute legal, regulatory, or professional advice.
Regulatory requirements, inspection expectations, and system obligations may vary based on jurisdiction, study design, technology, and organisational context. As such, the information presented here should not be relied upon as a substitute for project-specific assessment, validation, or regulatory decision-making.
We have no commercial relationship with some of the entities, vendors, or software referenced. Any examples are illustrative only, and usage may vary by organisation and their needs.
For guidance tailored to your organisation, systems, or clinical programme, we recommend speaking directly with us or engaging another suitably qualified subject matter expert (SME) to assess your specific needs and risk profile.
